Primary Angiitis of the Central Nervous System (PACNS): A Comprehensive Clinical Guide

1. Comprehensive Introduction & Overview

Primary Angiitis of the Central Nervous System (PACNS), also referred to as Primary CNS Vasculitis, is a rare, complex, and potentially life-threatening inflammatory disorder restricted to the blood vessels of the brain and spinal cord. Unlike systemic vasculitides, which affect multiple organ systems, PACNS is characterized by the absence of evidence for systemic inflammation or vessel involvement outside the central nervous system.

The clinical presentation of PACNS is notoriously heterogeneous, often mimicking stroke, malignancy, or neurodegenerative processes. Because of its rarity and the lack of pathognomonic clinical features, diagnosis is frequently delayed, leading to significant morbidity. This guide serves as an authoritative synthesis of current clinical knowledge, diagnostic criteria, and management strategies for the medical professional.

2. Etiology and Pathophysiology

The exact etiology of PACNS remains idiopathic. However, current research suggests it is an immune-mediated process triggered by unidentified antigens, potentially involving viral infections (e.g., Varicella-Zoster Virus), molecular mimicry, or autoimmune dysregulation.

The Mechanism of Vascular Injury

The pathophysiology involves a T-cell and macrophage-mediated inflammatory response targeting the small-to-medium-sized leptomeningeal and parenchymal arteries. The process unfolds in several stages:

1. Endothelial Activation: Cytokine release (IL-1, TNF-alpha) leads to the upregulation of adhesion molecules (ICAM-1, VCAM-1).
2. Leukocyte Recruitment: Monocytes and T-lymphocytes migrate through the blood-brain barrier (BBB) into the vessel walls.
3. Vessel Wall Destruction: The inflammatory infiltrate induces fibrinoid necrosis of the tunica media and intima.
4. Luminal Stenosis/Occlusion: The resulting wall thickening, intimal proliferation, and secondary thrombosis lead to cerebral ischemia or hemorrhage.
5. Parenchymal Damage: Chronic hypoperfusion results in multifocal infarction, encephalopathy, or cognitive decline.

3. Clinical Presentation and Staging

Standard Clinical Presentation

Patients typically present with a subacute or chronic course. The most common symptoms include:

• Headaches: Often severe, persistent, and refractory to conventional analgesics.
• Cognitive Impairment: Rapidly progressive dementia or executive dysfunction.
• Focal Neurological Deficits: Hemiparesis, aphasia, or visual field cuts (mimicking stroke).
• Seizures: Often focal, occurring in approximately 25% of patients.
• Encephalopathy: Confusion, personality changes, or altered consciousness.

Clinical Staging/Grading

While there is no formal "staging" system like in oncology, clinicians often categorize patients based on the modified Rankin Scale (mRS) and the Mini-Mental State Examination (MMSE) to track progression.

4. Differential Diagnosis

The diagnostic challenge lies in the extensive list of mimics. Practitioners must exclude the following before confirming PACNS:

• Reversible Cerebral Vasoconstriction Syndrome (RCVS): Characterized by "thunderclap" headaches and reversible vasoconstriction.
• Infectious Vasculitis: Syphilis, Lyme disease, VZV, or fungal infections (e.g., Aspergillus).
• Systemic Vasculitis: SLE, Polyarteritis Nodosa (PAN), or Behçet’s disease.
• Malignancy: Primary CNS lymphoma or intravascular lymphoma.
• Atherosclerotic Disease: Intracranial arterial stenosis.
• Genetic Conditions: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy).

5. Diagnostic Testing Protocols

The diagnostic workup for PACNS must be systematic to ensure high specificity.

Key Diagnostic Tools

1. MRI/MRA: The gold standard for initial evaluation. Findings include multifocal infarcts in different vascular territories, leptomeningeal enhancement, and vessel stenosis.
2. Cerebrospinal Fluid (CSF) Analysis: Often shows pleocytosis (lymphocytic), elevated protein levels, and occasionally elevated IgG index. CSF is critical to rule out infections.
3. Digital Subtraction Angiography (DSA): Traditionally the gold standard, showing a "beading" appearance of vessels. However, it has low sensitivity for small-vessel vasculitis.
4. Brain Biopsy: The definitive diagnostic test. A combined leptomeningeal and cortical biopsy provides the highest diagnostic yield, though it carries risks of morbidity.

6. Treatment and Management Strategies

Management is usually bifurcated into induction and maintenance phases.

Induction Therapy

• Corticosteroids: High-dose IV methylprednisolone (1g daily for 3–5 days), followed by a tapering course of oral prednisone.
• Cyclophosphamide: Often reserved for severe, progressive cases or those refractory to steroids. Administered via monthly IV pulses.

Maintenance Therapy

• Azathioprine or Mycophenolate Mofetil: Used to maintain remission and allow for the tapering of corticosteroids.
• Rituximab: Emerging as a therapeutic option for refractory cases, targeting B-cell populations.

7. Risks, Side Effects, and Contraindications

All immunosuppressive therapies carry significant risks:
* Infection: Increased susceptibility to opportunistic pathogens.
* Bone Marrow Suppression: Specifically with cyclophosphamide (monitor CBC).
* Steroid Toxicity: Osteoporosis, hyperglycemia, hypertension, and psychiatric disturbances.
* Biopsy Risks: Hemorrhage, seizures, or focal deficits at the biopsy site.

8. Long-Term Prognosis

The prognosis for PACNS has improved with modern aggressive immunosuppression. However, patients often require long-term monitoring for relapse.
* Survival: 5-year survival rates are significantly higher than historical figures, now exceeding 80–90% with appropriate treatment.
* Cognitive Outcomes: Many patients suffer from residual cognitive deficits, requiring neuro-rehabilitation.
* Relapse Risk: Approximately 25–30% of patients experience at least one relapse, necessitating prolonged maintenance therapy.

9. Frequently Asked Questions (FAQ)

Q1: How can I distinguish PACNS from RCVS?
A: RCVS typically presents with thunderclap headaches and shows rapid resolution of vasoconstriction on repeat imaging (within 12 weeks). PACNS shows progressive clinical decline and persistent or worsening vascular findings.

Q2: Is a brain biopsy always necessary?
A: Not always. If the clinical, CSF, and imaging findings are highly suggestive and infectious/systemic causes are ruled out, some clinicians initiate empirical treatment. However, biopsy remains the gold standard for definitive diagnosis.

Q3: What is the significance of "beading" on an angiogram?
A: It represents alternating areas of stenosis and dilation in small-to-medium vessels, which is a classic, though not pathognomonic, sign of vasculitis.

Q4: Can PACNS affect the spinal cord?
A: Yes, though rare, PACNS can manifest as myelitis, leading to sensory and motor deficits below the level of the lesion.

Q5: Are there any specific blood markers for PACNS?
A: No. Unlike systemic vasculitis, inflammatory markers like ESR and CRP are frequently normal in PACNS.

Q6: What is the role of Rituximab in PACNS?
A: While not FDA-approved specifically for PACNS, it is increasingly used as a steroid-sparing agent in refractory cases.

Q7: How often should I perform follow-up imaging?
A: Imaging frequency depends on clinical status. Generally, follow-up MRI is performed at 3, 6, and 12 months, or sooner if clinical symptoms progress.

Q8: Can PACNS occur in children?
A: Yes, pediatric PACNS exists and is often associated with more severe, rapid-onset clinical courses.

Q9: Is it possible for the biopsy to be negative in a patient with PACNS?
A: Yes, due to the "patchy" nature of the inflammation, a biopsy may miss the affected area (sampling error).

Q10: What is the most common cause of death in PACNS patients?
A: Death is usually secondary to complications of the disease (cerebral infarction or hemorrhage) or complications from long-term immunosuppressive treatment (severe infection).

10. Clinical Summary for Practitioners

Primary CNS Vasculitis is a diagnosis of exclusion. The physician must maintain a high index of suspicion in patients presenting with unexplained, progressive cognitive decline or multifocal neurological deficits. A multidisciplinary approach involving Neurology, Rheumatology, and Neuroradiology is essential. Early initiation of immunosuppression is the cornerstone of preventing permanent neurological destruction.

Disclaimer: This guide is for educational purposes for healthcare professionals and does not replace institutional clinical protocols or individualized patient judgment.